_:n06a32429822a4548a9ddeede7005f2c3xb0
<http://schema.org/datePublished>
<https://business.sherbrookerecord.com/sherbrookerecord/article/accwirecq-2024-8-19-nanoviricides-continues-its-march-towards-a-phase-ii-clinical-trial-of-nv-387-a-potentially-revolutionary-first-line-antiviral-therapy-for-rsv-covid-and-other-viral-infections>